GSGayane A. Shakaryants

Gayane A. Shakaryants

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gayane A. Shakaryants has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Structure of Concomitant Pathology in Patients With Hypertrophic Cardiomyopathy in The Older Age Group. Review and Clinical Observations

    by G. A. Shakaryants, Yu. N. Belenkov, V. Yu. Kaplunova, E. I. Tashina, D. A. Tyurina, N. V. Khabarova, A. V. Vysokykh, J. M. Kasaeva, L. V. Chkotua, E. V. Privalova

    Advances in modern drug and surgical treatment of patients with hypertrophic cardiomyopathy (HCM) have resulted in a significant increase in the life expectancy of these extremely severe patients. Therefore, in addition to the genetic markers, major neurohumoral systems and morpho-functional parameters of intracardiac hemodynamics, the course and prognosis of the disease are influenced by concomitant pathology. In infancy and early childhood, HCM is associated with tumors of chromaffin tissue of various localizations; however, the older the patient, the greater the likelihood of developing metabolic syndrome, secondary atherosclerosis and ischemic heart disease (IHD), and hypertension, which significantly complicates the verification of the HCM diagnosis. We have previously described cases of IHD secondary to HCM, which significantly affected the course and prognosis of both diseases. However, in old age, other comorbidities may also occur in addition to the diseases described above. Based on long-term observation of a large cohort of patients, this article analyzes a wide range of HCM combinations with pathology of other organs and systems, including malignant neoplasms, which makes significant adjustments to the treatment of both the underlying disease and cancer. The material is presented in the form of a brief review of literature on this topic and our own clinical observations and studies.

  • PROGNOSTIC ROLE OF NEUROHUMORAL AND EPIGENETIC MARKERS IN THE FORMATION OF PHENOTYPIC MANIFESTATIONS OF HYPERTROPHIC CARDIOMYOPATHY

    by Vysokikh A.V., Kaplunova V.Y., Shakaryants G.A., Tashina E.I., Privalova E.V., Belenkov Y.N.

    At the present time, the problem of studying hypertrophic cardiomyopathy (HCM) remains relevant due to the severity of this disease and the high risk of sudden cardiac death in the population, in particular in young and working age population, which can often be the first and only manifestation of this pathology. Consequently, the search for additional methods of early diagnosis and the development of tools for predicting the course of the disease remain priority areas of research in cardiology. Modern fundamental and clinical studies conducted all over the world are mostly focused on the search for relevant and accessible biomarkers in clinical practice of a doctor, among which special attention is paid to neurohumoral and epigenetic markers, which can be closely related to the possible outcome, the variant of the course of HCM in a patient, as well as can correlate with certain morphometric parameters according to the instrumental methods of examination and clinical picture, which in turn will later serve as a basis for a patient's personalised approach. These studies offer significant prospects for a patient personalised approach. Our review of the current literature on this topic is devoted to the analysis of current trends in cardiology, in particular, in the possible diagnosis and prognostic role of the course of HCM on the basis of neurohumoral and epigenetic markers. Particular attention is paid to the evaluation of the role of miR-29a and TGF-β 1 in patients with different variants of the course of HCM.

  • DEVELOPMENT OF A PERSONALIZED TECHNIQUE FOR EARLY DIAGNOSIS AND PREDICTION OF VARIANTS OF THE COURSE OF HYPERTROPHIC CARDIOMYOPATHY BASED ON THE ANALYSIS OF MICRORNAS-21, 29A, 133A

    by Tashina E.I., Kaplunova V.YU., Shakaryants G.A., Vysokykh A.V., Privalova E.V., Belenkov Yu.N.

    For many years, cardiovascular diseases have occupied and continue to occupy leading positions due to mortality and disability of the adult working-age population. Hypertrophic cardiomyopathy (HCM) is the most common variant of cardiomyopathy, its prevalence among the general population worldwide is 0.2% (1 in 500 adults). The study of the disease has been taking place for quite a long time, the half-century history of studying the problem of HCMP reflects a significant evolution of knowledge in matters of etiology, pathogenesis, diagnosis, clinical course and prognosis, variants of the course of the disease, however, there are still no methods of early diagnosis that could be used as a possible screening of this condition in the early stages and forecasting its more severe course. New methods could make it possible to diagnose this condition at an early stage and predict a possible course of its course, thereby preventing such a formidable complication as sudden cardiac death (SCD). At the moment, there is a prediction model (HCM Risk-SCD) for the risk of SCD, based on the results of instrumental research methods and anamnesis data of a particular patient, but this model is not perfect enough, and therefore it is gaining great popularity and the search for various biomarkers continues based on well-known scientific achievements in the field of genomics and transcriptomics. Perhaps in the near future, the study of the levels of certain microRNAs, which have already proven their affinity for the degree of myocardial hypertrophy, will become a new milestone in the study of hypertrophic cardiomyopathy.

  • Open Access

    Correlation between markers of fibrosis and myocardial remodeling in patients with various course of hypertrophic cardiomyopathy

    by F. M. Bogatyreva, V. Yu. Kaplunova, M. V. Kozhevnikova, G. A. Shakaryants, E. V. Privalova, Yu. N. Belenkov

    Aim. To assess the relationship between fibrosis markers and structural and functional parameters in patients with various types of hypertrophic cardiomyopathy (HCM).Material and methods. This prospective comparative non-randomized study included 49 patients with HCM. Patients were divided into 3 groups according to the disease course: group 1 — stable course (n=12; men, 8 (67%), mean age ‒ 41±12 years); group 2 — progressive course (n=26; men, men, 16 (61%). mean age — 57±11 years); group 3 — patients with atrial fibrillation (AF) (n=11; men, 4 (36%), mean age — 63±6 years). Patients underwent standard clinical and paraclinical investigations. The levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-1) were determined in all patients using enzyme-linked immunosorbent assay in blood serum.Results. In all patients with HCM, elevated levels of MMP-9 and TIMP-1 are noted compared to the reference values. In group 1, the MMP-9 level [Me (Q1; Q3)] was 226 (201;271) ng/ml; TIMP-1 — 410 (267;488) ng/ml; in group 2, the MMP-9 level was 236 (187;285) ng/ml; TIMP-1 — 421 (321;499) ng/ml. In the course with AF, the MMP-9 level was 260 (228;296) ng/ml, while TIMP-1 — 381,5 (305;466) ng/ml; no significant difference was revealed (p=0,59; p=0,90, respectively). A correlation was found between age and MMP-9 levels, as well as between MMP-9 levels and left atrial volume (p=0,034; p=0,035, respectively).Conclusion. The high activity of matrix metalloproteinases and their tissue inhibitors reflects enhanced fibrosis and myocardial remodeling in HCM, which is especially characteristic of patients with AF.


  • Assessment of the structural and functional state of blood vessels in patients with hypertrophic cardiomyopathy

    by F. M. Bogatyreva, V.RA Yu. Kaplunova, M. V. Kozhevnikova, G. A. Shakaryants, N. V. Khabarova, E. V. Privalova, Yu. N. Belenkov

    Aim      To evaluate the structural and functional condition of the vasculature using fingertip photoplethysmography and computerized videocapillaroscopy in patients with hypertrophic cardiomyopathy (HCMP). Material and methods  The study included patients with HCMP (n=48; 28 (57 %) men; age, 54.3±13.6 years) and healthy volunteers (control group, n=33, 15 (45 %) men; age, 58.2±8.8 years). Standard laboratory and instrumental examination (blood count and biochemistry, electrocardiography, echocardiography, Holter electrocardiogram monitoring) were performed for all HCMP patients. The condition of vascular wall at various levels of the vasculature was evaluated by fingertip photoplethysmography (apparatus Angioscan-01) and computerized nail-fold videocapillaroscopy (apparatus Capillaroscan-01). The photoplethysmography study analyzed structural parameters, including the arterial wall stiffness index (aSI) of large blood vessels and the resistance index (RI) of small muscular arteries. Endothelial dysfunction was evaluated by the occlusion index (OI) and phase shift (PS). The capillaroscopy study assessed structural parameters, including the resting capillary density (rCD) and the capillary density following venous occlusion (voCD), and functional parameters, including the percentage of perfused capillaries (PPC), the percentage of restored capillaries (PRC), and the capillary density after the reactive hyperemia test (rhCD). Results The study showed increases in aSI (8.8 [6.8; 12.2] and RI (32.5 [17.4; 47.9] in the HCMP group. The OI was significantly lower in the HCMP group (1.3 [1.1; 1.5]) than in the control group (1.8 [1.5; 2.7], рConclusion      In patients with HCMP, fingertip photoplethysmography and computerized videocapillaroscopy showed increased wall stiffness in both large blood vessels and microvasculature, pronounced endothelial dysfunction, and decreases in capillary density and percentage of restored capillaries following respective tests.


  • Open Access

    Assesment of Markers of Endothelial Dysfunction and Myocardial Stress in Patients with Hypertrophic Cardyomyopathy

    by F. M. Bogatyreva, V. Yu. Kaplunova, M. V. Kozhevnikova, G. A. Shakaryants, D. A. Yatsenko, А. V. Emelianov, A. S. Lishuta, N. V. Khabarova, E. V. Privalova, Yu. N. Belenkov

    Aim. To study the level of serum biomarkers of endothelial dysfunction and myocardial stress in patients with various types of hypertrophic cardiomyopathy (HCM).Material and Methods. 48 patients with hypertrophic cardiomyopathy (27 men and 21 women) were examined, the mean age was 54±13 years. The patients were divided into two groups according to the course options: group 1 - symptomatic stable course (n=14); group 2 - progressive course of symptomatic HCM (n=34). In accordance with the assigned tasks, all patients underwent determination of biological markers of neurohumoral systems in blood serum using immunofluorescence assay analysis: N-terminal fragment of brain natriuretic peptide (NT-proBNP), von Willebrand factor (vWF), endothelin-1, E-selectin with subsequent evaluation and correlation of results with clinical and instrumental characteristics of patients. When performing echocardiography following parameters were assessed: dimensions of the heart chambers, the thickness of the interventricular septum, the thickness of the posterior wall of the left ventricle (LV), LV mass, LV mass index, the ratio between LV filling in diastole (peak E) and atrial systole (peak A)-(E/A), relative myocardial thickness index, left atrial volume index.Results. Both groups showed increased levels of NT-proBNP and endothelin-1. E-selectin and vonWillebrand factor remained within the normal range. There was no statistically significant intergroup difference. There was a correlation between the level of the index of the relative myocardial thickness and the level of NT-proBNP (r=0.30; p=0.04). A correlation was found between the level of the vWF marker and the left atrial volume index (r=0.32; p=0.04). When assessing the association of indicators of intracardiac hemodynamics with other markers (E-selectin and endothelin-1, no statistically significant relationships were found.Conclusion. In the course of the research, it was found that the high activity of endothelin-1 and NT-proBNP reflects endothelial dysfunction and myocardial stress in patients with HCM, especially in patients with a progressive variant of HCM. However, we did not find any changes in the levels of E-selectin and von Willebrand factor, as well as their intergroup differences. These results require additional studies to assess endothelial dysfunction in patients with HCM.

  • Focus on the Myocardial Hypertrophy from the Perspective of Transcriptomics and Metabolomics

    by G. A. Shakaryants, M. V. Kozhevnikova, V. Yu. Kaplunova, E. V. Privalova, A. S. Lishuta, E. O. Korobkova, Yu. N. Belenkov

    This review presents major directions in studies of myocardial hypertrophy from the aspect of transcriptomics and metabolomics. Understanding of trigger mechanisms of myocardial hypertrophy will permit transition from basic studies to individualized clinical application of innovative technologies in the treatment of heart diseases, such as targeted therapy. At the present time, methods have been developed for diagnostics and prediction of cardiovascular diseases based on the metabolomic profiling and the evaluation of microRNA expression. Progress in studying molecular and genetic processes underlying the development of cardiovascular diseases may provide invaluable information for clinical cardiology.


  • Metabolomic profiling in patients with metabolic syndrome

    by E. O. Korobkova, M. V. Kozhevnikova, I. S. Ilgisonis, G. A. Shakaryants, S. A. Appolonova, A. V. Kukharenko, E. V. Larcova, A. A. Maltseva, N. V. Khabarova, Yu. N. Belenkov

    Objective. To identify biomarkers, which are most specific for patients with metabolic syndrome (MS) using metabolomic profiling. Materials and Methods. Metabolomic profiling of patients with MS and comparison of their profile with the profile of volunteers was performed using high-performance liquid chromatography-mass-spectrometry. Results. The metabolomic profile of MS patients differed in several amino acids, including choline, cysteine, and serine and in the acylcarnitine group (р<0.05 for all comparisons). Conclusion. The metabolites most specific for MS patients were identified. Increased concentrations of a combination of amino acids and carnitines can be considered as possible additional risk factors for cardiovascular diseases.


  • Treatment and secondary prevention of venous thromboembolism in cancer patients

    by G. A. Shakaryants, D. A. Budanova, K. V. Lobastov, N. V. Khabarova, Yu. Yu. Kirichenko, Yu. N. Belenkov

    Oncological patients are a high-risk group for venous thromboembolic complications. These complications significantly impair the outcome of antitumor treatment and take a leading place in the structure of mortality. Treatment of venous thromboembolic complications in oncological patients is a serious challenge. When selecting an anticoagulant, the physician should consider its efficacy and safety and possible drug interactions. Based on results of multiple studies presented in this article, physicians will be able to choose an optimum therapeutic tactics and secondary prevention of thromboembolic complications for this group of patients.


  • Vasoprotective Effects of Prolonged Therapy With Perindopril A in Patients with Hypertension Including Concomitant Type 2 Diabetes Mellitus

    by Yu. A. Danilogorskaya, E. A. Zheleznykh, E. A. Privalova, Yu. N. Belenkov, A. A. Shchendrigina, M. V. Kozhevnikova, G. A. Shakaryants, V. Yu. Zektser, A. S. Lishuta, N. V. Khabarova

    Objective Investigate the dynamics of morphological and functional markers of vascular remodeling in patients with arterial hypertension (AH), including those with concomitant type 2 diabetes mellitus (DM2), during 12-month administration of perindopril A. Material and Methods The study included patients with grade I-II AH, with and without DM2 (30 and 32 patients, respectively), who underwent outpatient correction of initially ineffective antihypertensive therapy and administration of perindopril A, 10 mg/day. Morphological and functional parameters of vascular remodeling were evaluated in all patients at baseline and at 12 months using photoplethysmography. Stiffness index (SI) and phase shift (PS) were measured in large vessels. Reflection index (RI) and occlusion index (OI) were measured in microvessels. Computed nailfold videocapillaroscopy was used to determine capillary density (CD) at rest (CDr), CD during venous occlusion test (CDvo), and CD during reactive hyperemia test (CDrh). Data are medians [interquartile range]. Results After 12-month administration of perindopril A, the morphological and functional parameters of vascular remodeling in AH patients without DM2 significantly improved at all vascular levels. SI decreased to 9.25 [7.8; 10.93 ] m/s and PS increased to 7.4 [5.6; 9.05] ms. In microvasculature, a statistically significant reduction was observed in RI, 31 [27; 36.5]%, and an increase was observed in OI, which characterizes endothelium function, 1.75 [1.68; 1.9]. Capillary CDr significantly increased to 40.5 [34.93; 46] cap/mm2, as did CDvo and CDrh. At the same time, in the group of patients with AH and DM2, a significant improvement was observed for the large vessels. SI decreased to 9.8 [9.08; 10.58] m/s, and PS increased to 6.95 [5.13; 10.08]. The RI index, reflecting the structural condition of arterioles, significantly decreased to 34 [25.9; 45.53]%, and the OI index, characterizing endothelial function, did not change significantly, 1.4 [1.3; 1.6]. Capillary CDr significantly increased to 31.55 [27.68; 34.7 ] cap/mm2; however, CDvo and CDrh did not change significantly. Renal function improved in both groups. Conclusion Both groups demonstrated improvement of morphological parameters at all levels of the arterial bed. However, patients with AH and concomitant DM2 showed no improvement of the endothelial function of arterioles and capillaries compared to improvement in AH patients without DM2. This reflected the more severe endothelial dysfunction present in AH patients with DM2.